TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33774105

Group type: EXPERIMENTAL
Intervention: Multi-stage technique education
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Duration-based teaching
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual training (Control)
Number of subjects: 155
Study: 32833050

Group type: EXPERIMENTAL
Intervention: Parasitized larvae (PL) with copepods
Number of subjects: 190

Group type: COMPARATOR
Intervention: Non-parasitized larvae (NPL)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Parasitized larvae (PL)
Number of subjects: 190
Study: 34232419

Group type: EXPERIMENTAL
Intervention: ASSIST intervention
Number of subjects: 91
Study: 34992881

Group type: EXPERIMENTAL
Intervention: Low dose radiation therapy (RT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 36310517

Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy intervention (exercise therapy and patient education)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: PTSS high group (HT)
Number of subjects: 115
Study: 35425844

Group type: COMPARATOR
Intervention: Control (3 mL of subcutaneous 0.5% bupivacaine)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HVIGI (10 mL of 0.5% bupivacaine and 30 mL of normal saline, ultrasound‐guided between tendon and underlying fat pad)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HVIGI with steroid (0.25 mL of 100 mg/mL hydrocortisone)
Number of subjects: 62
Study: 35310783

Group type: EXPERIMENTAL
Intervention: Nomogram prediction model for cancer-specific survival (CSS)
Number of subjects: 33509
Study: 35247102

Group type: EXPERIMENTAL
Intervention: Continuing ARB/CCB combination tablets (Group C)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Withholding ARB/CCB combination tablets (Group W)
Number of subjects: 106
Study: 33502511

Group type: EXPERIMENTAL
Intervention: 7-day point prevalence smoking abstinence
Number of subjects: 1751

Group type: EXPERIMENTAL
Intervention: 7-day abstinence from smoking and nicotine
Number of subjects: 1751

Group type: EXPERIMENTAL
Intervention: Six-month prolonged abstinence
Number of subjects: 1751
Study: 34558061

Group type: EXPERIMENTAL
Intervention: Psychoeducational program based on the rational emotional behavioral approach
Number of subjects: 0
Study: 34915452

Group type: EXPERIMENTAL
Intervention: Passive lower limb training (E1, E2, E3)
Number of subjects: 30
Study: 34847709

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Any medication (ISMN or cilostazol)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 27
Study: 32590960

Group type: EXPERIMENTAL
Intervention: CT and MRI analysis
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CT analysis
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MRI and CT analysis
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Quantitative analysis
Number of subjects: 29
Study: 35338177

Group type: EXPERIMENTAL
Intervention: Milvexian 50 mg daily for 14 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milvexian 200 mg daily for 14 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milvexian 500 mg daily for 14 days under fed conditions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milvexian (all doses)
Number of subjects: 32
Study: 34339232

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32723033

Group type: EXPERIMENTAL
Intervention: Speed of 11 km·h‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Speed of 12 km·h‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Speed of 13 km·h‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Speed of 14 km·h‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall effect of speed on all absolute values except push-off force
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Asymmetry in variables
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Increased gait speed
Number of subjects: 18
Study: 34551146

Group type: EXPERIMENTAL
Intervention: Hydrophobic narrow-diameter implants (Neoporos surface, NS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrophilic narrow-diameter implants (Acqua surface, AS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (NS)
Number of subjects: 16
Study: 33585276

Group type: EXPERIMENTAL
Intervention: Saliva
Number of subjects: 25101

Group type: EXPERIMENTAL
Intervention: Supragingival plaque
Number of subjects: 25101

Group type: EXPERIMENTAL
Intervention: Community‐Based Cohort Study
Number of subjects: 25101

Group type: EXPERIMENTAL
Intervention: Birth and Three‐Generation Cohort Study
Number of subjects: 25101

Group type: EXPERIMENTAL
Intervention: Co-occurrence network analysis
Number of subjects: 25101
Study: 33593462

Group type: EXPERIMENTAL
Intervention: Synbiotic ice cream supplementation for 30 days containing 2·1 × 10^8 CFU/g for Lactobacillus acidophilus LA‐5, 2·7 × 10^9 CFU/g for Bifidobacterium animalis BB‐12, and 2·3 g of inulin in 60 g of ice cream.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo ice cream.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups (synbiotic and placebo).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Synbiotic ice cream supplementation.
Number of subjects: 65
Study: 35182217

Group type: EXPERIMENTAL
Intervention: Blue Laser Imaging (BLI)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 164
Study: 33939625

Group type: EXPERIMENTAL
Intervention: Tweets indicating capability factors (P<.001)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Tweets indicating motivation factors (P<.001)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Tweets indicating opportunity factors (P=.03)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Overall behavioral intentions from tweets
Number of subjects: 5000
Study: 33384892

Group type: EXPERIMENTAL
Intervention: Gradient-boosting decision tree model using preoperative biometry and patient sex as predictors
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Gradient-boosting decision tree model excluding keratometry
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Gradient-boosting decision tree model using IOL power as an additional predictor
Number of subjects: 847

Group type: COMPARATOR
Intervention: Five existing methods (control)
Number of subjects: 847
Study: 32905628

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Serum glucose levels
Number of subjects: 859
Study: 32349543

Group type: EXPERIMENTAL
Intervention: Core stability training (24 sessions)
Number of subjects: 44
Study: 34789539

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systemic treatment
Number of subjects: 0
Study: 32735711

Group type: EXPERIMENTAL
Intervention: 30‐mm 6‐0, 5‐0, and 4‐0 nylon monofilaments
Number of subjects: 22
Study: 35246227

Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg administered enterally every 8 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35712945

Group type: EXPERIMENTAL
Intervention: Wei's triple nine needling combined with esculin and digitalis glycosides eye drops
Number of subjects: 46

Group type: COMPARATOR
Intervention: Esculin and digitalis glycosides eye drops alone
Number of subjects: 46
Study: 33602209

Group type: EXPERIMENTAL
Intervention: Papacarie‐Duo
Number of subjects: 162

Group type: COMPARATOR
Intervention: ART
Number of subjects: 162
Study: 33140104

Group type: EXPERIMENTAL
Intervention: Jeopardy-style educational game show-based intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional didactic-based curriculum
Number of subjects: 38
Study: 35020871

Group type: EXPERIMENTAL
Intervention: Racemic ketamine (0.5 mg/kg) infusions
Number of subjects: 186

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 186
Study: 34518580

Group type: EXPERIMENTAL
Intervention: Maxillary sinus saline irrigation after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Caldwell-Luc procedure
Number of subjects: 40
Study: 33065070

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 30
Study: 32514736

Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Existing healthcare and patient-generated data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring patient safety in randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study design and methodological options specific to PCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best practices to ensure data quality in PCTs
Number of subjects: 0
Study: 34342619

Group type: EXPERIMENTAL
Intervention: Active management (uterine evacuation followed by methotrexate if needed)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Active management (empirical methotrexate using a 2-dose protocol)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 255
Study: 32229417

Group type: EXPERIMENTAL
Intervention: Tertiary education
Number of subjects: 9255

Group type: EXPERIMENTAL
Intervention: Secondary education
Number of subjects: 9255
Study: 36112726

Group type: EXPERIMENTAL
Intervention: Year 4 trainees
Number of subjects: 100

Group type: COMPARATOR
Intervention: Year 3 trainees
Number of subjects: 100

Group type: COMPARATOR
Intervention: Year 2 trainees
Number of subjects: 100
Study: 35297138

Group type: EXPERIMENTAL
Intervention: Intralesional PPD with low dose isotretinoin for a 3-month course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intralesional PPD monotherapy at 2-week intervals for up to six sessions
Number of subjects: 0
Study: 34768411

Group type: EXPERIMENTAL
Intervention: HILT (7 W, 149.9 J/cm2, 1064 nm, 4496 J, 12 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham HILT therapy (placebo)
Number of subjects: 60
Study: 33896825

Group type: EXPERIMENTAL
Intervention: Platinum plus etoposide chemotherapy (CT)
Number of subjects: 911
Study: 32064794

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg QD from days 1 to 14 of a 21-day cycle)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 35273066

Group type: EXPERIMENTAL
Intervention: Management guided by both ICP and PbtO2 monitoring
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Management guided by ICP alone
Number of subjects: 1094
Study: 33618193

Group type: EXPERIMENTAL
Intervention: Integrated exposure therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Integrated coping skills therapy
Number of subjects: 110
Study: 32756078

Group type: EXPERIMENTAL
Intervention: Sancai powder (SC) combined with western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 60
Study: 33085787

Group type: EXPERIMENTAL
Intervention: New insights into prostate cancer biology and treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs and drug targets in prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advances in prostate cancer genomics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lessons from the multi‐arm, multistage randomized phase 3 STAMPEDE trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advances in immunotherapy for prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors contributing to prostate cancer racial disparities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment‐associated small‐cell/neuroendocrine prostate cancer (t‐SCNC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial intelligence and machine learning in cancer research and development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population science research on prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostate cancer research in the Department of Veterans Affairs
Number of subjects: 0
Study: 32493240

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (IIM-Diafer®)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Iron sucrose (IS-Venofer®)
Number of subjects: 190
Study: 86062952

Group type: EXPERIMENTAL
Intervention: 2 mug of HBsAg intradermally on days 0, 30, and 180
Number of subjects: 50

Group type: COMPARATOR
Intervention: 20 mug of HBsAg intramuscularly on days 0, 30, and 180
Number of subjects: 50
Study: 36066864

Group type: EXPERIMENTAL
Intervention: Digital narrative-based bibliotherapy (reading one suicide narrative per day for 14 days)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 528
Study: 33436401

Group type: EXPERIMENTAL
Intervention: Metformin alone for 12 months
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Glargine for 3 months followed by metformin for 9 months
Number of subjects: 438
Study: 36111381

Group type: EXPERIMENTAL
Intervention: 75 mg of DIM (administered as 300 mg of DIM‐BR®) for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35976136

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 33765679

Group type: EXPERIMENTAL
Intervention: Low-dose exercise training at 4-7 days/week
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 43
Study: 34211323

Group type: EXPERIMENTAL
Intervention: Dominant knee extensors (KE) fatigue intervention (2×100s MVC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (equivalent rest)
Number of subjects: 12
Study: 33296385

Group type: EXPERIMENTAL
Intervention: Some support
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Approach-oriented goals
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Avoidance-oriented goals
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Extended support
Number of subjects: 1066
Study: 35235082

Group type: EXPERIMENTAL
Intervention: LEDT plus HIIT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo plus HIIT
Number of subjects: 16
Study: 34404606

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Health Education and Wellness training (HEW)
Number of subjects: 178
Study: 32614699

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg/day for 8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Teriparatide and Placebo
Number of subjects: 34
Study: 35894434

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No PFMT (Control)
Number of subjects: 104
Study: 34750366

Group type: EXPERIMENTAL
Intervention: Disinfectant spray
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Disinfectant wipe
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (not cleaned)
Number of subjects: 72
Study: 34648751

Group type: EXPERIMENTAL
Intervention: Nipple shields for persistent nipple pain
Number of subjects: 25
Study: 34543939

Group type: EXPERIMENTAL
Intervention: Emotional intelligence training (twice a week for one month, then once a week for 11 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (daily briefings without emotional intelligence training)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Emotional intelligence training
Number of subjects: 103
Study: 32065620

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg/day, 48 hours intravenous infusion)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 58
Study: 36343592

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg single oral dose)
Number of subjects: 21832

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 21832
Study: 33530942

Group type: EXPERIMENTAL
Intervention: Low-dose TXA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose TXA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32902312

Group type: EXPERIMENTAL
Intervention: Nivolumab (N) alone or combined with ipilimumab (I) as neoadjuvant therapy after 6 months of adjuvant therapy
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard therapy as first-line treatment
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Nivolumab (N) alone or combined with ipilimumab (I)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 276
Study: 35973802

Group type: EXPERIMENTAL
Intervention: Rituximab induction therapy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cyclophosphamide/azathioprine
Number of subjects: 189
Study: 33533690

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis positive contacts (N = 82)
Number of subjects: 891

Group type: COMPARATOR
Intervention: Chlamydia trachomatis negative contacts
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis positive contacts
Number of subjects: 891
Study: 34753815

Group type: EXPERIMENTAL
Intervention: Small-volume nebulizer (SVN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer (VMN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Face mask with exhalation filter (SVN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mouthpiece with exhalation filter (VMN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exhalo scavenger over the mask (SVN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vapotherm scavenger and filter face mask
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mouthpiece
Number of subjects: 9

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 9
Study: 33269509

Group type: EXPERIMENTAL
Intervention: DFF-based glucose fluctuation metric
Number of subjects: 137
Study: 33872452

Group type: EXPERIMENTAL
Intervention: Pretest score for HIT diagnosis
Number of subjects: 2280
Study: 32312242

Group type: EXPERIMENTAL
Intervention: Telemedication review using tele-expertise
Number of subjects: 364

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 364
Study: 35022178

Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy, delivered by specialised exercise and physical therapists, a multimodal and tailored treatment based on the biopsychosocial model.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy, delivered by specialised exercise and physical therapists.
Number of subjects: 20
Study: 34682735

Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 100

Group type: COMPARATOR
Intervention: Biscuits
Number of subjects: 100
Study: 32300013

Group type: EXPERIMENTAL
Intervention: Brief video-based training for teachers to change language used to introduce science.
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Baseline control condition where teachers described scientists as a special kind of person.
Number of subjects: 1100
Study: 35277773

Group type: EXPERIMENTAL
Intervention: STAR intervention (text messaging reminders)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (standard post-operative education)
Number of subjects: 35
Study: 33416214

Group type: EXPERIMENTAL
Intervention: Survivorship care plan (SCP) plus mobile app
Number of subjects: 224

Group type: COMPARATOR
Intervention: Survivorship care plan (SCP) only
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 224
Study: 36047732

Group type: EXPERIMENTAL
Intervention: Real-time, electronic alert-triggered, patient-centered education bundle
Number of subjects: 11098

Group type: COMPARATOR
Intervention: Nurse feedback intervention
Number of subjects: 11098
Study: 33994084

Group type: EXPERIMENTAL
Intervention: Volar plate group
Number of subjects: 62

Group type: COMPARATOR
Intervention: External fixator group
Number of subjects: 62
Study: 35663978

Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab and pertuzumab treatment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combined prediction model using HER2/CEP17 ratio, CD8 levels, and histological grade
Number of subjects: 159
Study: 33691266

Group type: EXPERIMENTAL
Intervention: Memory Flexibility (MemFlex) intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Psychoeducation about cognitive-behavioral mechanisms
Number of subjects: 74
Study: 35274092

Group type: EXPERIMENTAL
Intervention: Low-dose azathioprine (median dose 50 mg) combined with allopurinol (100 mg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Azathioprine monotherapy (median dose 200 mg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Low-dose azathioprine combined with allopurinol
Number of subjects: 89

Group type: COMPARATOR
Intervention: Azathioprine monotherapy
Number of subjects: 89
Study: 33901566

Group type: EXPERIMENTAL
Intervention: ADT + DERT76
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: ADT + RT70
Number of subjects: 600

Group type: COMPARATOR
Intervention: DERT76
Number of subjects: 600
Study: 33726766

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 32636292

Group type: EXPERIMENTAL
Intervention: Immediate skin-to-skin contact (SSC) with a parent
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional care in an incubator
Number of subjects: 150
Study: 34719982

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No anticoagulation (NA)
Number of subjects: 31
Study: 32444401

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol (200/6 μg Turbuhaler, one actuation)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol
Number of subjects: 110
Study: 34490700

Group type: EXPERIMENTAL
Intervention: Insulin degludec U100
Number of subjects: 180

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 180